Eli Lilly and Company (NYSE:LLY) Shares Bought by Richelieu Gestion SA

Richelieu Gestion SA raised its holdings in Eli Lilly and Company (NYSE:LLY) by 59.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 929 shares of the company’s stock after buying an additional 347 shares during the period. Richelieu Gestion SA’s holdings in Eli Lilly and Company were worth $723,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. PGIM Custom Harvest LLC boosted its holdings in Eli Lilly and Company by 20.6% in the 3rd quarter. PGIM Custom Harvest LLC now owns 1,657 shares of the company’s stock valued at $890,000 after purchasing an additional 283 shares in the last quarter. One Charles Private Wealth Services LLC acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $215,000. O Shaughnessy Asset Management LLC raised its position in shares of Eli Lilly and Company by 9.7% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 107,042 shares of the company’s stock worth $57,495,000 after purchasing an additional 9,459 shares during the last quarter. Milestone Asset Management LLC grew its stake in Eli Lilly and Company by 4.1% in the 3rd quarter. Milestone Asset Management LLC now owns 759 shares of the company’s stock worth $409,000 after acquiring an additional 30 shares during the period. Finally, Mckinley Capital Management LLC grew its stake in Eli Lilly and Company by 51.3% in the 3rd quarter. Mckinley Capital Management LLC now owns 7,675 shares of the company’s stock worth $4,123,000 after acquiring an additional 2,602 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 92,563 shares of the stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the transaction, the insider now owns 98,556,247 shares in the company, valued at approximately $79,752,700,634.87. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Lilly Endowment Inc sold 92,563 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $809.21, for a total transaction of $74,902,905.23. Following the completion of the transaction, the insider now owns 98,556,247 shares in the company, valued at $79,752,700,634.87. The disclosure for this sale can be found here. Insiders have sold a total of 789,704 shares of company stock worth $672,385,964 in the last 90 days. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Down 0.4 %

Shares of NYSE:LLY traded down $3.23 during mid-day trading on Wednesday, hitting $901.38. The stock had a trading volume of 1,099,551 shares, compared to its average volume of 2,932,382. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $909.42. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. The company has a market cap of $856.68 billion, a PE ratio of 132.89, a P/E/G ratio of 1.97 and a beta of 0.36. The company’s 50 day moving average is $804.54 and its 200-day moving average is $734.18.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The company had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. During the same quarter in the prior year, the firm earned $1.62 EPS. The company’s revenue was up 26.0% compared to the same quarter last year. On average, sell-side analysts predict that Eli Lilly and Company will post 13.76 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price target on shares of Eli Lilly and Company in a research report on Monday. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, April 3rd. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Finally, Argus upped their price target on shares of Eli Lilly and Company from $770.00 to $840.00 and gave the stock a “buy” rating in a research report on Tuesday, May 14th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $812.72.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.